MTAAPHIL
Market cap576mUSD
Dec 20, Last price
19.10EUR
1D
0.00%
1Q
-4.50%
IPO
23.23%
Name
Philogen SpA
Chart & Performance
P/E
—
P/S
23.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.60%
Rev. gr., 5y
10.80%
Revenues
23m
-2.46%
Net income
-6m
L+14.60%
CFO
-3m
L-34.14%
Earnings
Apr 29, 2025
Profile
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 23,130 -2.46% | 23,713 850.04% | 2,496 -47.76% | ||||
Cost of revenue | 38,292 | 29,315 | 23,472 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (15,162) | (5,602) | (20,976) | ||||
NOPBT Margin | |||||||
Operating Taxes | (20) | 1,017 | 485 | ||||
Tax Rate | |||||||
NOPAT | (15,142) | (6,619) | (21,461) | ||||
Net income | (6,161) 14.60% | (5,376) -65.81% | (15,725) 18.37% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (2,379) | (1,924) | 64,867 | ||||
BB yield | 0.32% | ||||||
| Debt | |||||||
Debt current | 1,889 | 871 | 743 | ||||
Long-term debt | 25,126 | 22,911 | 22,941 | ||||
Deferred revenue | 1,507 | 1,962 | 4,620 | ||||
Other long-term liabilities | 3,128 | 3,948 | 1,000 | ||||
Net debt | (48,329) | (65,405) | (75,662) | ||||
| Cash flow | |||||||
Cash from operating activities | (3,253) | (4,939) | (19,031) | ||||
CAPEX | (5,545) | (4,211) | (6,818) | ||||
Cash from investing activities | 159 | 24,197 | (47,771) | ||||
Cash from financing activities | (4,173) | (3,782) | 63,055 | ||||
FCF | (17,929) | (11,140) | (26,999) | ||||
| Balance | |||||||
Cash | 75,344 | 86,200 | 101,677 | ||||
Long term investments | 1 | 2,987 | (2,331) | ||||
Excess cash | 74,188 | 88,001 | 99,221 | ||||
Stockholders' equity | (6,586) | (6,164) | (9,526) | ||||
Invested Capital | 113,910 | 121,217 | 130,767 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 40,247 | 40,415 | 39,645 | ||||
Price | 18.50 | ||||||
Market cap | 744,578 | ||||||
EV | 696,249 | ||||||
EBITDA | (11,521) | (2,820) | (19,114) | ||||
EV/EBITDA | |||||||
Interest | 547 | 406 | 403 | ||||
Interest/NOPBT | |||||||